Nefrogen systemisk fibros

1. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentate dimeglumine. Invest Radiol 2009; 44: 135-9. PubMed  
2. Hellman R. Gadolinium-induced Nephrogenic Systemic Fibrosis. Seminars in Nephrology 2011; 3: 310-6. PubMed  
3. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260: 105-11. Radiology  
4. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-4. PubMed  
5. Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006; 21: 1104-8. PubMed  

• Nils Grefberg, med dr och överläkare internmedicin och nefrologi, tidigare vid Medicinkliniken, Centrallasarettet Växjö

Tidigare sakkunniga

• Åse Kjellmo, överläkare, Klinikk for Bildediagnostikk, St.Olavs Hospital, Trondheim
• Ingard Løge, specialist allmänmedicin, redaktör Norsk Elektronisk Legehåndbok